Astorg Acquires Majority Interest in Avania
Avania announced that Astorg has acquired a majority stake in the company, which will actively support management’s plans to advance Avaina’s development as MedTech solution provider. Astorg has an extensive global network of relationships in the MedTech space which will aid to strengthen Avania’s pipeline and broaden their customer base all while capital access accelerating its growth. The platform will assist Avania to try to be ahead of the MedTech CRO space and will bring additional investments to the infrastructure.
Read more about this news release here.
New machine-learning approach could speed precision drug development
The approach, detailed this week in the journal Nature, uses a platform called Molecular Surface Interaction Fingerprinting (MaSIF) to design custom proteins that bind to drug-bound target proteins.
AI-enabled CGM app shows promise for glycemic control, weight management
The broader implications of this study suggest that digital health platforms like January V2 have the potential to play a crucial role in the future of chronic disease management,” the authors write.
